Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00264290 · ClinicalTrials.gov registry record · Phase 4
Valganciclovir to Reduce T Cell Activation in HIV Infection
A Phase 4 study, sponsored by University of California, San Francisco.
- Completed
- Registry status
- Phase 4
- Development phase
- 30
- Enrollment target
NCT00264290 is a Phase 4 study that has completed, run by University of California, San Francisco. The registered enrollment target is 30 participants.
The verdict
NCT00264290, a Phase 4 study, has completed, sponsored by University of California, San Francisco.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 30 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether treatment with valganciclovir decreases T cell activation levels among HIV-infected patients with asymptomatic cytomegalovirus (CMV) co-infection, potentially improving immune responses to antiretroviral therapy.
Interventions
- DRUG Placebo
- DRUG Valganciclovir
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2006-08 |
| Est. Completion | 2008-11 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00264290
The ClinicalTrials.gov registry entry for NCT00264290 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00264290 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00264290 about?
NCT00264290 is a clinical study titled "Valganciclovir to Reduce T Cell Activation in HIV Infection". The purpose of this study is to determine whether treatment with valganciclovir decreases T cell activation levels among HIV-infected patients with asymptomatic cytomegalovirus (CMV) co-infection, potentially improving immune responses to antiretroviral therapy.
What is the current status of trial NCT00264290?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 30 participants. The study started on 2006-08. Estimated completion is 2008-11.
What interventions are being tested in trial NCT00264290?
The interventions under investigation include: Placebo (DRUG), Valganciclovir (DRUG).
Who is sponsoring clinical trial NCT00264290?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.